Acute Heart Failure Developing During Azacitidine Therapy: A Retrospective Report

Azacitidine is a chemotherapeutic agent used to treat myelodysplastic syndrome (MDS). In our hospital, a relatively large proportion of patients (25%) given azacitidine developed acute heart failure (HF) associated with a high fatality rate (40%), although no prior research has identified acute HF as a major side effect of azacitidine therapy.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Yui Kambara, Yusuke Meguri, Hiroyuki Sugiura, Akira Yamamoto, Tomohiro Urata, Taiga Kuroi, Taro Masunari, Nobuo Sezaki, Toru Kiguchi Source Type: research